WSGR logoWSGR logo
Jennifer D. Knapp
Partner
Corporate
Palo Alto

D650-849-3041

Download vCard
LinkedIn
Open PDF
  • Comprehensive Corporate and Securities Experience

    Jennifer represents clients in a wide range of corporate compliance and transactional matters, including formation and structuring,  venture financings, corporate governance, spin-ins and spin-outs, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance issues.

  • Represents Innovative Technology Companies and Leading Investors

    Jennifer represents innovative technology and life sciences clients, as well as leading venture capital firms and institutional investors.

Jennifer Knapp represents public and private companies across all stages of growth and a broad range of sectors, as well as venture capital and other institutional investors. She focuses on the representation of companies throughout their entire life cycle from formation to exit, and in all manner of strategic and complex transactions, including corporate formation and structuring, venture capital financings, corporate governance, spin-ins and spin-outs, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance matters. She also has significant experience advising investors with respect to venture capital financings and other strategic investments and transactions.

Experience

Jennifer Knapp represents public and private companies across all stages of growth and a broad range of sectors, as well as venture capital and other institutional investors. She focuses on the representation of companies throughout their entire life cycle from formation to exit, and in all manner of strategic and complex transactions, including corporate formation and structuring, venture capital financings, corporate governance, spin-ins and spin-outs, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance matters. She also has significant experience advising investors with respect to venture capital financings and other strategic investments and transactions.

Focus Areas
Recent Insights
News Articles
IFLR1000 Recognizes Wilson Sonsini Practices, Attorneys in 2024 Guide
In the 2024 edition of its annual guide, IFLR recognized Wilson Sonsini practices and attorneys for their work in the financial and corporate sectors in the U.S. and China. The guide uses in-depth market analysis and interviews with practitioners and clients to determine leading financial and corporate law firms worldwide. Wilson Sonsini’s rankings are summarized below.
Learn More
Client Highlights
Wilson Sonsini Advises Denali Therapeutics on $500 Million Private Placement Financing
On February 27, 2024, California-based Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, announced that it has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share and pre-funded warrants to purchase 26,046,065 shares of common stock at a purchase price of $17.06 per pre-funded warrant share, through a private investment in public equity (PIPE) financing. Denali Therapeutics anticipates gross proceeds from the PIPE to be approximately $500 million. Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the transaction.
Learn More
View All
WSGR logo
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.